加载中
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
前收盘价
US$1.06
−US$0.14 · -11.67%
盘中时间采用ET。市场数据可能有所延迟。
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
日内区间
当前US$1.06
52周区间
当前US$1.06
盘中时间采用ET。市场数据可能有所延迟。
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
日内区间
当前US$1.06
52周区间
当前US$1.06
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 17万 USD | 100万 USD | — | — | — |
| 销货成本 | 14.6万 USD | — | — | — | — |
| 毛利 | 2.4万 USD | 100万 USD | — | — | — |
| 研究与开发 | 794.9万 USD | 1133.4万 USD | 1273.4万 USD | 4346万 USD | 1757.6万 USD |
| 销售、一般及管理费用 | 1043万 USD | 1207.5万 USD | 1297.4万 USD | 1414.1万 USD | 1147.4万 USD |
| 营业费用 | 1823.3万 USD | 2340.9万 USD | 2570.8万 USD | 5760.1万 USD | 2905万 USD |
| 利息收入 | 80.6万 USD | 188.3万 USD | 272.4万 USD | 105.2万 USD | 15.1万 USD |
| 折旧和摊销 | 14.6万 USD | 17.4万 USD | 18.9万 USD | 6.9万 USD | 5.5万 USD |
| 营业利润 | −1820.9万 USD | −2240.9万 USD | −2570.8万 USD | −5760.1万 USD | −2905万 USD |
| 净利润 | −1658.6万 USD | −1998.5万 USD | −2084万 USD | −5422.5万 USD | −2746.6万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
年度分割调整后的每股现金分配。
US$0.31
2013年（完整年度）+24.0% 自从 2011
US$0.25
2,011
US$0.31
2,013
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2013年10月28日 | US$0.0021Special | — | — |
股息 | 2011年4月4日 | US$0.0002Special | — | — |
除息 2013年10月28日
US$0.0021
Special
除息 2011年4月4日
US$0.0002
Special
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI28.51万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF11.99万0.00%954亿 USD0.05%US$235+0.80%
Dimensional - US Sustainability Core 1 ETFDFSU1200.00%23.92亿 USD0.15%US$48.11+0.48%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR9.60.00%455.91亿 USD0.17%US$84.44+0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
